Abstract:Background: Neuroblastoma is the most common extracranial solid tumor in children and accounts for 15% of pediatric cancer related deaths. Targeting neuroblastoma with immunotherapies has proven challenging due to a paucity of immune cells in the tumor microenvironment and the release of immunosuppressive cytokines by neuroblastoma tumor cells. We hypothesized that combining an oncolytic Herpes Simplex Virus (oHSV) with natural killer (NK) cells might overcome these barriers and incite tumor cell death. Methods: We utilized MYCN amplified and non-amplified neuroblastoma cell lines, the IL-12 expressing oHSV, M002, and the human NK cell line, NK-92 MI. We assessed the cytotoxicity of NK cells against neuroblastoma with and without M002 infection, the effects of M002 on NK cell priming, and the impact of M002 and priming on the migratory capacity and CD107a expression of NK cells. To test clinical applicability, we then investigated the effects of M002 and NK cells on neuroblastoma in vivo. Results: NK cells were more attracted to neuroblastoma cells that were infected with M002. There was an increase in neuroblastoma cell death with the combination treatment of M002 and NK cells both in vitro and in vivo. Priming the NK cells enhanced their cytotoxicity, migratory capacity and CD107a expression. Conclusions: To the best of our knowledge, these investigations are the first to demonstrate the effects of an oncolytic virus combined with self-maintaining NK cells in neuroblastoma and the priming effect of neuroblastoma on NK cells. The current studies provide a deeper understanding of the relation between NK cells and neuroblastoma and these data suggest that oHSV increases NK cell cytotoxicity towards neuroblastoma.

Research therapeutic advances of oncolytic virus for neuroblastoma

Progress of Oncolytic Virotherapy for Neuroblastoma

Clinical and pathological analysis of the olfactory neuroblastoma

Oncolytic virus therapy for malignant gliomas: entering the new era

Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma

Recent advances in molecular genetic characterization of high-risk neuroblastoma

Clinical Advances and Future Directions of Oncolytic Virotherapy for Head and Neck Cancer

Recent advances in targeting cancer stem cells using oncolytic viruses

Clinical advances in oncolytic virotherapy for pediatric brain tumors

The emerging field of viroimmunotherapy for pediatric brain tumors

Targeting the ubiquitin-proteasome system: a novel therapeutic strategy for neuroblastoma

Oncolytic virotherapies for pediatric tumors

Clinical Advances in Oncolytic Virus Therapy for Malignant Glioma: a Systematic Review

Recent oncolytic virotherapy clinical trials outline a roadmap for the treatment of high-grade glioma

Advancing therapy for neuroblastoma

Oncolytic virotherapy augments self-maintaining natural killer cell line cytotoxicity against neuroblastoma

Development and application of oncolytic viruses as the nemesis of tumor cells

Development of Differentiation Modulators and Targeted Agents for Treating Neuroblastoma.

From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

Gospel of malignant Glioma: Oncolytic virus therapy